The results of the current study regarding the poor prognostic impact of TGF-β1 overexpression are consistent with those of Ivanović et al (21) and Dave et al (38), who observed increased levels of plasma TGF-β1 in locally advanced BC (stages III and IV). The gene discussed is TGFB1; the disease is breast cancer.